Qiagen stock gains after Morgan Stanley raises price target and new CEO outlines margin focus

Published on 09/15/2026 at 14:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock moved higher on September 14, 2026 after Morgan Stanley lifted its price target and reiterated a positive stance. The company now targets an EBIT margin of about 29.5 percent for fiscal year 2024, matching an earlier 2028 goal.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen N.V. stock (ISIN NL0012169213) attracted fresh investor interest after a Morgan Stanley price target increase and new strategic details from Chief Executive Jonathan Pratt, with the Xetra-quoted shares closing at 36.91 euros on September 14, 2026, up 1.05 percent from the prior session.

Morgan Stanley raises target as management highlights margins

As Ad-hoc-news.de reported on September 14, 2026, Morgan Stanley lifted its price target for Qiagen and issued a buy signal on the shares, a move that coincided with a gain of about 0.36 euros or roughly 0.99 percent to around 36.89 euros in Xetra trading at the time of that report.

According to Investing.com on September 14, 2026, Qiagen used the Morgan Stanley 24th Annual Global Healthcare Conference to underline that it is on track to end fiscal year 2024 with an EBIT margin above 29 percent, equating to about 29.5 percent at constant exchange rates, compared with an earlier 2028 target of 31 percent once dilution from the Parse acquisition and tariff effects are factored in.

In the same conference appearance, Chief Financial Officer Roland Sackers emphasized that Qiagen is aiming for an annual free cash flow of approximately 500 million euros and maintains a net debt to EBITDA ratio below 1.0, reinforcing management’s message that the company’s balance sheet can support ongoing investment and share repurchases while still meeting margin goals, as highlighted by Investing.com on September 14, 2026.

Operational trends and segment dynamics

According to Investing.com on September 14, 2026, Qiagen has recorded 3 percent growth in its Sample Technologies segment for three consecutive quarters on an underlying basis excluding PATH, illustrating that core consumables demand is expanding steadily even without contributions from certain partnership revenues.

The same conference update indicated that PATH-related revenue exceeded 45 million euros compared with an original plan of 40 million euros, meaning that this stream came in more than 12.5 percent above the company’s initial projection for the period, while automation, digital PCR and several infectious disease testing products also delivered growth, as discussed by management in the Morgan Stanley presentation documented by GuruFocus on September 14, 2026.

Management reiterated that these operational trends underpin the margin guidance, noting that the move to an EBIT margin of about 29.5 percent for fiscal year 2024 would represent a meaningful step up compared with historical levels; at the same time, Qiagen continues to operate a share buyback program equal to 10 percent of share capital plus an additional 200 million dollars, signaling confidence in the company’s cash generation capacity, according to Investing.com.

Stock price context and investor perspective

Qiagen stock closed on Xetra at 36.91 euros on September 14, 2026, after trading between an intraday low near 36.53 euros and an intraday high around 37.06 euros, with the 1.05 percent advance from the previous close of 36.53 euros occurring on a turnover of just under 60,000 shares, according to Xetra data cited by Ad-hoc-news.de.

At that level, the stock’s valuation was described as being supported by a price to earnings ratio of 21.49, placing Qiagen among opportunities on an undervalued list compared with a calculated fair value range, as Investing.com noted on September 14, 2026.

The combination of an EBIT margin target of approximately 29.5 percent for fiscal year 2024, three quarters of 3 percent underlying growth in Sample Technologies and PATH revenue coming in more than 12.5 percent above plan provides investors with a quantitatively backed picture of operational progress, while the recent Morgan Stanley price target increase and buy rating add an external validation layer to the company’s narrative.